AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
taurolidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2568 | 19388-87-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Taurolidine, an antimicrobial agent employed for infection prevention in catheters, has received FDA approval in conjunction with heparin. This approval is specifically for reducing the occurrence of catheter-related bloodstream infections in adult patients with kidney failure who undergo chronic hemodialysis utilizing a central venous catheter (CVC).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK7,MAPKAPK2,PDK1,PDK2,PDK4,PRKDC,TEK | 18 | |||
| kinase-selectivity-class | ACVRL1,AXL,BMX,BRAF,CAMK2D,CDK1,CDK16,CDK4,CDK6,CDK7,CDK9,CHUK,DYRK1A,EGFR,EPHB4,ERBB2,ERBB4,FLT3,IRAK1,IRAK3,IRAK4,MAP2K6,MAP3K21,MAPK14,PIK3CB,PIK3CD,SIK2,TEK,TGFBR1 | 29 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05CA05 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS IRRIGATING SOLUTIONS Antiinfectives |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| MeSH PA | D000970 | Antineoplastic Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35718 | antifungal agent |
| CHEBI has role | CHEBI:48218 | antiseptic drug |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
Related Drugs by ATC class:
B05CA Antiinfectives 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Prevention of catheter related bloodstream infection | indication | 736442006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.59 | acidic |
| pKa2 | 11.19 | acidic |
| pKa3 | 4.83 | Basic |
| pKa4 | 1.0 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | 7696182 | May 16, 2026 | A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER |
| 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | 7696182 | May 16, 2026 | A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | Nov. 15, 2028 | NEW CHEMICAL ENTITY |
| 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | Nov. 15, 2028 | NEW CHEMICAL ENTITY |
| 3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | Nov. 15, 2033 | GENERATING ANTIBIOTIC INCENTIVES NOW |
| 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML) | DEFENCATH | CORMEDIX | N214520 | Nov. 15, 2023 | RX | SOLUTION | N/A | Nov. 15, 2033 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D07146 | KEGG_DRUG |
| 4043261 | VANDF |
| C0144567 | UMLSCUI |
| CHEBI:135173 | CHEBI |
| CHEMBL2105420 | ChEMBL_ID |
| DB12473 | DRUGBANK_ID |
| C012566 | MESH_SUPPLEMENTAL_RECORD_UI |
| 29566 | PUBCHEM_CID |
| 13030 | IUPHAR_LIGAND_ID |
| 2885 | INN_ID |
| 8OBZ1M4V3V | UNII |
| 2670453 | RXNORM |
| 27243 | MMSL |
| 006823 | NDDF |
| 1287715004 | SNOMEDCT_US |
| 281000220103 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| DEFENCATH | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72990-103 | SOLUTION | 40.50 mg | INTRALUMINAL | NDA | 26 sections |
| DEFENCATH | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72990-103 | SOLUTION | 40.50 mg | INTRALUMINAL | NDA | 26 sections |
| DEFENCATH | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72990-105 | SOLUTION | 67.50 mg | INTRALUMINAL | NDA | 26 sections |
| DEFENCATH | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72990-105 | SOLUTION | 67.50 mg | INTRALUMINAL | NDA | 26 sections |